Impact of blood volume, tube shaking, and incubation time on the reproducibility
|
|
- Ruby Gray
- 6 years ago
- Views:
Transcription
1 JCM Accepts, published online ahead of print on 21 August 2013 J. Clin. Microbiol. doi: /jcm Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 Impact of blood volume, tube shaking, and incubation time on the reproducibility of QuantiFERON-TB Gold In-Tube assay 3 Rajiv L. Gaur a, Madhukar Pai b, and Niaz Banaei a,c,d# a Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA. b Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada. c Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA. d Clinical Microbiology Laboratory, Stanford University School of Medicine, Stanford, CA, USA. Running Title: Sources of QuantiFERON-TB Gold In-Tube variability # To whom correspondence should be addressed Hillview Ave, Room Palo Alto, CA Phone: Fax:
2
3 20 Abstract Interferon gamma release assays (IGRAs) are functional assays used serially to measure the efficacy of novel tuberculosis (TB) vaccines and to screen health care workers for latent tuberculosis infection (LTBI). Yet, studies are showing non-reproducible IGRA results. In this study we investigated the effect of blood volume (0.8, 1.0, and 1.2 ml), tube shaking (gentle vs. vigorous), and incubation duration (16, 20, and 24 hour) on the reproducibility of QuantiFERON-TB Gold In-Tube (QFT-GIT) results in 50 (33 uninfected and 17 infected) subjects. The median IFN-γ TB response (TB Antigen (Ag) minus Nil) was significantly higher with 0.8 ml blood (1.04 IU/ml) compared to 1.0 ml (0.85 IU/ml; P=0.002) and 1.2 ml (0.49 IU/ml; P<0.001) in subjects with LTBI. Compared to 0.8 ml (11.8%), there were higher proportions of false negative results with 1.0 ml (29.4%; P=0.2) and 1.2 ml (41.2%; P=0.05) of blood in infected subjects. Blood volume did not significantly change the proportion of positive results in uninfected controls. Compared to gentle shaking, vigorous shaking increased the median IFN-γ response in Nil (0.04 vs IU/ml; P<0.001) and TB Ag (0.12 vs IU/ml; P=0.004) tubes and increased TB response (TB Ag Vigorous minus Nil Gentle ) (0.02 vs. 0.08, P=0.004). The duration of incubation did not have a significant impact on the proportion of positive results in uninfected or infected subjects. This study identified blood volume and tube shaking as novel preanalytical sources of variability which require further standardization in order to improve the quality and reproducibility of QFT-GIT results.
4 42 43 Introduction There are 2 billion individuals worldwide with latent tuberculosis infection (LTBI) (1). Treatment of LTBI is a proven strategy for preventing progression of LTBI to active disease (2, 3). Interferon gamma (IFN-γ) release assays (IGRAs) are relatively new assays developed as an alternative to tuberculin skin test (TST) for diagnosis of LTBI. IGRAs are functional assays that measure T cell response to Mycobacterium tuberculosis-specific antigens, such as ESAT-6, CFP-10 and TB7.7, in whole blood or blood-derived mononuclear cells (4). Two Food and Drug Administration-approved commercial IGRAs are currently available: the QuantiFERON-TB Gold In-Tube assay (QFT-GIT; Qiagen, Carnegie, Australia) and the T-SPOT.TB assay (Oxford Immunotec, Abingdon, United Kingdom). IGRAs have improved specificity and offer logistical advantages as compared to TST (4). In recent years, IGRAs have replaced TST for annual screening of health care workers (HCWs) in many occupational health programs in North America (5, 6). In addition, IGRA conversion rate is now being used as a secondary measure of vaccine efficacy in tuberculosis (TB) vaccine trials (7). Despite much optimism for commercial IGRAs, studies in the past decade have revealed significant variability in IGRA sensitivity and reproducibility (4-6, 8-10). The sensitivity of IGRAs in culture-positive active TB cases has ranged from 65% to 100% (4, 8, 9). In contact investigation studies, the sensitivity of IGRAs for LTBI in patients that progressed to active TB ranged from 40% to 100% (10).
5 Furthermore, studies conducted in HCWs in low incidence settings have shown highly variable IGRA results with serial testing. The rate of conversions (negative to positive result) using the manufacturer recommended cut-offs ranged from 2% to 15% and the rate of reversions (positive to negative result) ranged from 20% to 40% (6, 11). The conversion rates in these studies were higher than expected based on the risk of TB infection in low incidence settings and TST conversion rates. Recent studies have identified several sources of variability related to assay manufacturing, preanalytical processing, analytical testing, and immunological boosting and modulation (12-16). However, causes of the broad IGRA variability in sensitivity and reproducibility are not fully understood. The suboptimal reproducibility and accuracy of IGRAs have important implications for occupational health and vaccine trials performing serial testing. In HCWs, false-negative results can lead to nosocomial outbreaks and false positives can result in excessive treatment and additional testing (17). In vaccine trials, false results can exaggerate or underestimate the protective efficacy of a vaccine candidate. Therefore, it is critical to identify and eliminate or standardize the predictable sources of variability. In this study we investigated the effect of blood volume, the extent of tube shaking and the duration of incubation of tubes on TB response with QFT-GIT assay in a cohort of healthy HCWs both with and without LTBI. 84
6 85 Methods Study Design. In a prospective study recruiting HCWs, we compared quantitative and qualitative QFT-GIT results after varying (i) blood volume, (ii) tube shaking, and (iii) incubation duration. A schematic overview of the study design is shown in Figure 1. This study was approved by the Stanford University IRB. Study Subjects. Healthy HCWs were recruited from the Stanford University Medical Center Clinical Laboratories. After obtaining consent, subjects were asked to complete a standardized self-questionnaire including information on age, gender, ethnicity, country of birth, countries visited for at least 6 months, BCG vaccination history, prior TST and QFT-GIT results, known exposure to M. tuberculosis, chest X-ray results, and immune status. Prior QFT-GIT results were confirmed in the laboratory information system. Volunteers were invited to enroll if they met criteria for (i) having LTBI (prior history of positive TST ( 10 mm) or QFT-GIT and 1 TB risk factor) or (ii) being an uninfected control (US born with prior negative TST or QFT-GIT and no TB risk factors). Volunteers were excluded if they reported signs or symptoms of active TB. The demographic data and prior results are presented in Table QuantiFERON-TB Gold In-Tube testing. Except for the experimental modifications described below, all tests were performed according to the QFT- GIT package insert (18). Blood was collected by a trained phlebotomist in a 10 ml Kendall Monoject Green Stopper tube and 1 ml was immediately transferred
7 to each QFT-GIT tube. Tubes were shaken gently by inverting the tubes 10 times according to package insert and immediately incubated for 24 hours. Plasma was separated and stored at room temperature up to 8 hours before a quantitative enzyme-linked immunosorbent assay (ELISA) for IFN-γ, measured in IU/ml, was performed on a DSX automated system (Dynex Technologies, Chantilly, VA). One IFN-γ ELISA plate was designated for all testing for each subject. Interpretation of results was done by the software provided by the QFT- GIT manufacturer. A positive result was defined per manufacturer as TB response (TB Ag minus Nil) value 0.35 IU/ml and 25% of Nil value. Blood volume. One milliliter of blood was transferred into each of the QFT-GIT blood collection tubes. In addition, 0.8 and 1.2 ml of blood was transferred into two additional TB Ag tubes. IFN-γ TB response was determined for each blood volume using the same Nil result. The volume of blood drawn directly into QFT- GIT tubes was also determined. In randomly selected group of volunteers (n=30), blood was drawn directly into a Nil and TB Ag vacutainer tubes of the same lot number at sea level until the tube appeared filled close to the indicator line, according to the package insert. Immediately after, the blood volume in each tube was measured using a calibrated pipette Tube Shaking. One milliliter of blood was transferred into each of the two sets of Nil and TB Ag tubes. One set was mixed gently by inverting the tubes 10 times according to package insert, ensuring that the entire inner surface of the tube was coated with the blood. The second set was held in one hand and mixed by
8 vigorously shaking the tubes in an up-and-down motion for 10 seconds. The blood transfer and tube shaking were performed by the same technologist for all study subjects. Immediate incubation of tubes and ELISA were performed as described above Incubation period. One milliliter of blood was transferred into three sets of QFT- GIT tubes. After mixing the content according to package insert, the sets were incubated at 37 C either for 16, 20, or 24 hours, respectively. ELISA was performed as described above. Statistical analysis. A non-parametric test, the Wilcoxon signed-rank test of medians, was used to compare differences between paired results. The chisquared test was used to determine the statistical significance of the difference between proportions. All statistical tests were computed for a two-sided type I error rate of 5%. Statistical analyses were performed using the Prism software (GraphPad, San Diego, CA). Results Effect of blood volume on TB response. According to the package insert, the standard QFT-GIT vacutainer tubes are calibrated to draw between 0.8 ml and 1.2 ml blood at altitudes from sea-level to 2,650 feet. To determine the distribution of blood volume drawn into QFT-GIT tubes, blood volume drawn into
9 the Nil tube and TB Ag tube from 30 subjects was measured. As shown in Figure 2A, the blood volume in the Nil and TB Ag tubes ranged from ml to 1.0 ml (median, ml; CV, 5.8%) and ml to ml (median, ml; CV, 4.7%), respectively To investigate the effect of blood volume variability on QFT-GIT results, IFN-γ TB response (TB Ag minus Nil) with 0.8, 1.0, and 1.2 ml of blood per TB Ag tube and 1.0 ml per Nil tube was measured. Results were available for the three blood volumes in 50 (33 uninfected and 17 infected) subjects (Table 2). In uninfected volunteers, the median TB response was significantly higher with 0.8 ml blood (0.01 IU/ml) compared to 1.0 ml (0 IU/ml; P=0.03) and 1.2 ml (0 IU/ml; P=0.04) (Figure 2B). One subject turned positive with 1.2 ml blood, but there was no significant difference in the proportion of positive results between the three blood volumes. In infected subjects, the median TB response was significantly higher with 0.8 ml blood (1.04 IU/ml) compared to 1.0 ml (0.85 IU/ml; P=0.002) and 1.2 ml (0.49 IU/ml; P<0.001) (Figure 2C). 88.2% (15/17) of infected subjects were positive with 0.8 ml blood, 70.6% (12/17) with 1.0 ml blood, and 58.8% (10/17) with 1.2 ml blood (Table 2). The proportion of subjects with positive results was significantly lower with 1.2 ml compared to 0.8 ml (P = 0.05) Effect of tube shaking on TB response. To investigate the effect of blood mixing variability on QFT-GIT results, tubes inoculated with equal volume of blood were mixed either gently or vigorously. Results were available for 40 (23 uninfected and 17 infected) subjects. The median IFN-γ concentration with
10 gentle and vigorous shaking was 0.04 and 0.06 IU/ml in the Nil tube and 0.12 and 0.24 IU/ml in the TB Ag tube, respectively (Table 3). Compared to gentle shaking, there was a significant increase in median IFN-γ level in the Nil and TB Ag tube with vigorous shaking (P<0.001 and P=0.004, respectively; Figure 3). Although the median TB response did not change significantly between gentle (0.02 IU/ml) and vigorous (0.03 IU/ml) shaking, the median TB response increased significantly when vigorously-shaken TB Ag response was paired with gently-shaken Nil response (Tb Ag Vigorous minus Nil Gentle ; P<0.001) and decreased significantly when gently-shaken TB Ag response was paired with vigorously-shaken Nil response (Tb Ag Gentle minus Nil Vigorous ; P=0.004) (Table 3 and Figure 3). There was no significant difference between the proportion of positive results with gentle (32.5%) and vigorous shaking (35.0%) but the proportion of positive results increased to 42.5% for Tb Ag Vigorous minus Nil Gentle and decreased to 27.5% for Tb Ag Gentle minus Nil Vigorous (Table 3). Effect of incubation duration on TB response. According to the package insert, the QFT-GIT tubes should be incubated between 16 and 24 hours. To determine the effect of incubation duration on TB response, QFT-GIT tubes from 50 (33 uninfected and 17 infected) subjects were incubated at 37 C for 16, 20, and 24 hours. The median TB response in uninfected subjects was 0, 0, and 0 IU/ml and in infected subjects was 0.66, 0.96, and 0.85 IU/ml for 16, 20, and 24- hour incubations, respectively (Table 4 and Figure 4). Except for 16 compared to 24 hours (P=0.04) in the uninfected group, the median TB response was not significantly different between the three incubation times in the uninfected or
11 infected subjects (Table 4 and Figure 4). No reversions or conversions were observed in the infected and uninfected subjects (Figure 4) Discussion In this study we investigated the role of blood volume, tube shaking, and incubation duration in reproducibility of the QFT-GIT assay. We showed that blood volume and tube shaking represent novel preanalytical sources of variability that likely contribute to discordant IGRA results in individuals undergoing serial testing. The impact of blood volume variability on TB response is most concerning for false-negative results in patients with TB infection. We showed that compared to 0.8 ml, inoculation of TB Ag tube with 1.0 and 1.2 ml of blood, which are within the range reported by the manufacturer, resulted in 17.6% and 29.4% reduction, respectively, in positive results in infected subjects. Although blood volume correlated with TB response in uninfected subjects, there were no false positive results with 0.8 ml blood in uninfected subjects. Thus, in addition to improving QFT-GIT reproducibility, our findings suggest standardizing blood volume to 0.8 ml may also increase assay sensitivity. In a recent study that included culture-confirmed adult patients, it was shown that 0.3 ml blood per QFT microtube, a modified version of QFT-GIT that requires 0.3 ml blood per tube, resulted in a TB response similar to that obtained with 1.0 ml blood added to standard QFT-GIT tubes (19). Interestingly, TB response with 0.3 ml blood was significantly higher than with 1.0 ml when higher antigen concentration (3
12 μg/ml) was used in the microtube. Altogether, these findings suggest a smaller blood volume (or increased antigen concentration) may improve detection of TB response in infected individuals. Further studies are needed to determine the optimum blood volume for maximizing QFT-GIT sensitivity without compromising specificity. A limitation of this study includes not including an assessment of the impact of blood volume on the IFN-γ concentration in the Nil tube. We also confirmed heterogeneity in the volume of blood drawn into TB Ag tubes (range, ml to ml; CV, 4.7%). Factors that contribute to blood volume variability include blood pressure of the individual at the time of blood draw, the position of vacutainer tube relative to venipuncture site, and altitude where blood is being drawn. Blood pressure has not been correlated with TB response in previous reproducibility studies but it may be an important factor that accounts for some of the within-subject variability observed in serial testing studies. The manufacturer of QFT-GIT produces two types of blood collection tubes; one tube type is calibrated for low altitude (sea-level to 2,650 feet) blood collection while the second type is produced for high (3,350 and 6,150 feet) altitude use. Users outside these altitude ranges (between 2,650 and 3,350 feet or above 6,150 feet) are instructed to collect blood using a syringe and transfer 1 ml to each of the three tubes. Future studies are needed to investigate the effect of altitude on blood volume drawn into standard and high altitude QFT-GIT tubes The impact of rigorous tube shaking on QFT-GIT results would depend on whether the Nil and TB Ag tubes are shaken identically or not. We showed that
13 vigorous shaking caused a significant increase in TB response when vigorouslyshaken TB Ag response was paired with gently-shaken Nil response and a significant decrease in TB response when gently-shaken TB Ag response was paired with vigorously-shaken Nil response. These results imply that if the Nil and TB antigen tubes are shaken separately as blood is sequentially drawn into the Nil and TB Ag tube, respectively, there is a possibility that differential shaking will result in an either false positive or false negative QFT-GIT result, especially when TB response is bordering the assay cut-off of 0.35 IU/ml. In the absence of a preventative TB vaccine (7), LTBI treatment remains the only proven strategy for preventing progression of latent infection to active disease (2). Epidemic modeling studies suggest that eradication of LTBI in high burden countries is necessary for successful elimination of TB (20, 21). Given the critical role IGRAs serve in identifying those individuals that need prophylactic treatment, it is imperative that we apply the knowledge gained from reproducibility studies to improve the sensitivity and reproducibility of IGRAs. Emphasis on the rigorous standardization of all controllable variables, two of which are highlighted in this study, is necessary to optimize the QFT-GIT assay. For example, blood volume variability can be avoided by collecting blood using a syringe and transferring an equal volume of blood into each QFT-GIT tube. A less standardized, but more practical, approach may include direct blood draws in the QFT-GIT tubes with close monitoring of the blood level relative to the 1.0 ml indicator line. Variable shaking can be minimized if all three tubes are simultaneously mixed gently in one hand. Alternatively, a roller mixer instrument may prove more effective for
14 standardization of mixing. Incubation delay is another preanalytical source of variability that has been shown to negatively impact TB response in IGRAs (12, 22-25). Immediate incubation of QFT-GIT can be achieved with the use of a portable incubator in the field or placement of an incubator in the phlebotomy station as reported previously (12, 26, 27). However, not all sources of variability can be eliminated through assay standardization. There is a need for a borderline zone to account for unpredictable variation that occurs due to random sources of error such as analytical (13). The contribution of each of the three preanalytical variables to IGRA variability in this study proved to be mechanistically counter-intuitive. For example, one might hypothesize that higher blood volume would yield a greater TB response due to higher number of antigen presenting cells (APCs) and T cells. To the contrary, we found that 0.8 ml of blood produces a significantly higher TB response compared to 1.0 and 1.2 ml of blood. This phenomenon is likely related to higher ratio of TB antigen to APCs and or T cells. The importance of antigen availability for T cell activation has been previously described for initiation of adaptive immunity but its effect on stimulation of effector T cells in IGRAs is not documented (28). Similarly, one might also hypothesize that the length of time T cells are stimulated with TB antigens correlates with IFN-γ release; therefore longer incubation of QFT-GIT tubes would lead to greater TB response. To the contrary, we did not find a significant change in TB response in infected subjects when QFT-GIT tubes were incubated for 16, 20, or 24 hours. Our finding, however, is inconsistent with an unpublished study showing a significantly lower
15 TB response with shorter incubation times (16-17 hours vs hours) (29). The enhanced IFN-γ release with vigorous shaking of the Nil and TB Ag tubes was also unexpected given that, until recently, the QFT-GIT package insert instructed users to mix the tubes by SHAKING VIGOROUSLY for 5 seconds to ensure that the entire inner surface of the tube has been coated with the blood. The mechanism through which vigorous shaking stimulates T cells to release IFN-γ is not known, but it may occur through direct and or indirect activation of blood cells. Shear forces are well known stimuli for dose and time dependent activation of platelets (30). In summary, we identified blood volume and tube shaking as previously unrecognized preanalytical sources of IGRA variability. With many sources of variability becoming known, studies are now needed to quantify the improvements in IGRA reproducibility and accuracy after elimination or standardization of systematic sources of variability. Acknowledgements We thank Mady Slater for reviewing the manuscript and the study subjects for participating in this study References
16 World Health Organization Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response Anonymous Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep. 49: Bucher, H. C., L. E. Griffith, G. H. Guyatt, P. Sudre, M. Naef, P. Sendi, and M. Battegay Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. Aids. 13: Menzies, D., M. Pai, and G. Comstock Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann. Intern. Med. 146: Ringshausen, F. C., A. Schablon, and A. Nienhaus Interferongamma release assays for the tuberculosis serial testing of health care workers: a systematic review. J. Occup. Med. Toxicol. 7:6. 6. Zwerling, A., S. van den Hof, J. Scholten, F. Cobelens, D. Menzies, and M. Pai Interferon-gamma release assays for tuberculosis screening of healthcare workers: a systematic review. Thorax. 67: Tameris, M. D., M. Hatherill, B. S. Landry, T. J. Scriba, M. A. Snowden, S. Lockhart, J. E. Shea, J. B. McClain, G. D. Hussey, W. A. Hanekom, H. Mahomed, H. McShane, and the MVA85A 020 Trial Study Team Safety
17 and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 381: Diel, R., R. Loddenkemper, and A. Nienhaus Evidence-based comparison of commercial interferon-γ release assays for detecting active TB: A metaanalysis. Chest. 137: Mazurek, M., J. Jereb, A. Vernon, P. LoBue, S. Goldberg, K. Castro, IGRA Expert Committee, and Centers for Disease Control and Prevention (CDC) Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, MMWR Recomm Rep. 59: Herrera, V., S. Perry, J. Parsonnet, and N. Banaei Clinical Application and Limitations of Interferon-γ Release Assays for the Diagnosis of Latent Tuberculosis Infection. Clin. Infect. Dis. 52: Pai, M., and K. Elwood Interferon-gamma release assays for screening of health care workers in low tuberculosis incidence settings: dynamic patterns and interpretational challenges. Can. Respir. J. 19: Doberne, D., R. L. Gaur, and N. Banaei Preanalytical delay reduces sensitivity of QuantiFERON-TB gold in-tube assay for detection of latent tuberculosis infection. J. Clin. Microbiol. 49:
18 Metcalfe, J. Z., A. Cattamanchi, C. E. McCulloch, J. D. Lew, N. P. Ha, and E. A. Graviss Test Variability of the Quantiferon-TB Gold In-Tube Assay in Clinical Practice. Am. J. Respir. Crit. Care Med. 187: Slater, M., J. Parsonnet, and N. Banaei Investigation of falsepositive results given by the QuantiFERON-TB Gold In-Tube assay. J. Clin. Microbiol. 50: Gaur, R. L., M. M. Suhosk, and N. Banaei In vitro immunomodulation of a whole blood IFN-γ release assay enhances T cell responses in subjects with latent tuberculosis infection. PLoS One. 7:e van Zyl-Smit, R. N., A. Zwerling, K. Dheda, and M. Pai Withinsubject variability of interferon-γ assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. PLoS One. 4:e8517. doi: /journal.pone Menzies, D., R. Joshi, and M. Pai Risk of tuberculosis infection and disease associated with work in health care settings. Int. J. Tuberc. Lung Dis. 11: Cellestis QuantiFERON-TB Gold. PACKAGE INSERT. Cellestis, Valencia, CA.
19 Rose, M. V., G. Kimaro, I. Kroidl, M. Hoelscher, I. C. Bygbjerg, S. M. Mfinanga, and P. Ravn Evaluation of QuantiFERON microtube, using 0.9 ml blood, for diagnosing tuberculosis infection. Eur. Respir. J. 41: Abu-Raddad, L. J., L. Sabatelli, J. T. Achterberg, J. D. Sugimoto, I. M. Longini Jr, C. Dye, and M. E. Halloran Epidemiological benefits of moreeffective tuberculosis vaccines, drugs, and diagnostics. Proc. Natl. Acad. Sci. U. S. A. 106: Blower, S. M., A. R. McLean, T. C. Porco, P. M. Small, P. C. Hopewell, M. A. Sanchez, and A. R. Moss The intrinsic transmission dynamics of tuberculosis epidemics. Nat. Med. 1: Beffa, P., A. Zellweger, J. P. Janssens, P. Wrighton-Smith, and J. P. Zellweger Indeterminate test results of T-SPOT.TB performed under routine field conditions. Eur. Respir. J. 31: Doherty, T. M., A. Demissie, D. Menzies, P. Andersen, G. Rook, A. Zumla, and VACSEL Study Group Effect of sample handling on analysis of cytokine responses to Mycobacterium tuberculosis in clinical samples using ELISA, ELISPOT and quantitative PCR. J. Immunol. Methods. 298: Hanekom, W. A., J. Hughes, M. Mavinkurve, M. Mendillo, M. Watkins, H. Gamieldien, S. J. Gelderbloem, M. Sidibana, N. Mansoor, V. Davids, R. A. Murray, A. Hawkridge, P. A. Haslett, S. Ress, G. D. Hussey, and G. Kaplan.
20 Novel application of a whole blood intracellular cytokine detection assay to quantitate specific T-cell frequency in field studies. J. Immunol. Methods. 291: Smith, S. G., S. A. Joosten, V. Verscheure, A. A. Pathan, H. McShane, T. H. Ottenhoff, H. M. Dockrell, and F. Mascart Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis. PLoS One. 4:e Dominguez, M., A. Smith, G. Luna, M. F. Brady, J. Austin-Breneman, S. Lopez, R. Yataco, and D. A. Moore The MIT D-lab electricity-free PortaTherm TM incubator for remote testing with the QuantiFERON-TB Gold In- Tube assay. Int. J. Tuberc. Lung Dis. 14: Herrera, V., E. Yeh, K. Murphy, J. Parsonnet, and N. Banaei Immediate incubation reduces indeterminate results for QuantiFERON-TB Gold in-tube assay. J. Clin. Microbiol. 48: Catron, D. M., L. K. Rusch, J. Hataye, A. A. Itano, and M. K. Jenkins CD4+ T cells that enter the draining lymph nodes after antigen injection participate in the primary response and become central-memory cells. J. Exp. Med. 203: Whitworth, W. C., G. H. Mazurek, and D. J. Goodwin Assay Parameters Affecting Variability of Quantiferon-Tb Gold In-Tube Assay Results,
21 abstr A4728. Abstr. Am. Thor. Soc. Internat. Conf. American Thoracic Society. San Francisco, CA Kroll, M. H., J. D. Hellums, L. V. McIntire, A. I. Schafer, and J. L. Moake Platelets and shear stress. Blood. 88:
22 Figure 1. Schematic overview of the study design. Subjects underwent QuantiFERON-TB Gold In-Tube (QFT-GIT) testing to investigate the effects of blood volume variability, shaking variability, and incubation duration variability on results. TB Ag, TB Antigen. 421
23 422
24 Figure 2. The effect of blood volume variability on QuantiFERON-TB Gold In- Tube (QFT-GIT) results. (A) Distribution of blood volume drawn into Nil and TB Ag tubes in 30 subjects. TB Ag, TB Antigen; CV%, coefficient of variance. (B and C) IFN-γ TB Ag-Nil values for 33 uninfected (B) and 17 infected (C) subjects tested with the indicated blood volumes in TB Ag tube. The assay cut-off for positive results (TB Ag-Nil value 0.35 IU/ml) is marked with a dashed line. Values <0 IU/ml are shown as 0 IU/ml. Wilcoxon signed-rank test was used to compare differences in medians. Downloaded from on April 10, 2018 by guest
25 Figure 3. The effect of tube shaking on QuantiFERON-TB Gold In-Tube results. (A and B) IFN-γ values in Nil (A) and TB Ag (B) tube with gentle and vigorous shaking. (C) IFN-γ TB Ag-Nil values with gentle and vigorous shaking. Data is representative of 40 (23 uninfected and 17 infected) subjects. The assay cut-off for positive results (TB Ag-Nil value 0.35 IU/ml) is marked with a dashed line. Values <0 IU/ml are shown as 0 IU/ml. Wilcoxon signed-rank test was used to compare differences in medians. TB Ag, TB Antigen; Gen, gentle; Vig, vigorous. 441
26 Downloaded from Figure 4. The effect of incubation duration variability on QFT-GIT results. (A and B) IFN-γ TB Ag-Nil values for 33 uninfected (A) and 17 infected (B) subjects tested with indicated duration of incubation. The cut-off for positive results (TB Ag-Nil value 0.35 IU/ml) is marked with a dashed line. Values <0 IU/ml are shown as 0 IU/ml. Wilcoxon signed-rank test was used to compare differences in medians. on April 10, 2018 by guest
27 Table 1. Demographic data and LTBI risk factors for the study subjects. Parameters a Number (%) of subjects Sex Male 19 (38) Female 31 (62) Age 44 ± 13.7 b Ethnicity White 22 (44) Asian 18 (36) African/African American 1 (2) Hawaiian/Pacific Islander 3 (6) Indian Continent 5 (10) Native American 1 (2) Place of Birth USA 19 (38) Foreign Country 31 (62) Previous TST result Negative 29 (58) Positive 17 (34) NA 4 (8) QFT-GIT result Negative 29 (58) Positive 17 (34) NA 4 (8) a NA, not available. b Mean age (in years) ± standard deviation
28 Table 2. QuantiFERON-TB Gold In-Tube results with variable blood volume. Subjects TB Ag Nil Median (Range) 0.8 ml 1.0 ml 1.2 ml P value % Positive TB Ag Nil Median (Range) % Positive TB Ag Nil Median (Range) % Positive 0.8 vs. 1.0 ml 0.8 vs. 1.2 ml Uninfected (n=33) 0.01 ( ) ( ) ( ) vs. 1.2 ml Infected (n=17) 1.04 ( ) ( ) ( ) <0.001 <0.001 TB Ag, TB Antigen; P value is for TB Ag-Nil Downloaded from on April 10, 2018 by guest
29 Table 3. QuantiFERON-TB Gold In-Tube results with variable tube shaking. TB Response Median (range) P value* % Positive (n=40) P value* Nil Gen 0.04 ( ) Nil Vig 0.06 ( ) < TB Ag Gen 0.12 ( ) TB Ag Vig 0.24 ( ) Tb Ag Gen - Nil Gen 0.02 ( ) Tb Ag Vig - Nil Vig 0.03 ( ) Tb Ag Gen - Nil Vig 0.00 ( ) < Tb Ag Vig - Nil Gen 0.08 ( ) Vig, vigorous; Gen, gentle *Compared to gentle shaking: Nil Gen, Tb Ag Gen and Tb Ag Gen - Nil Gen
30 Table 4. QuantiFERON-TB Gold In-Tube results with variable incubation duration. Subjects TB Ag Nil Median (Range) 16 hr 20 hr 24 hr P value % Positive TB Ag Nil Median (Range) % Positive TB Ag Nil Median (Range) % Positive Uninfected (n=33) 0.00 ( ) ( ) ( ) Infected (n=17) 0.66 ( ) ( ) ( ) TB Ag, TB Antigen; hr, hours; P value is for TB Ag-Nil 16 vs. 20 hr 16 vs. 24 hr 20 vs. 24 hr Downloaded from on April 10, 2018 by guest
Immediate Incubation Reduces Indeterminate Results for QuantiFERON-TB Gold In-Tube Assay
JOURNAL OF CLINICAL MICROBIOLOGY, Aug. 2010, p. 2672 2676 Vol. 48, No. 8 0095-1137/10/$12.00 doi:10.1128/jcm.00482-10 Copyright 2010, American Society for Microbiology. All Rights Reserved. Immediate Incubation
More informationEffect of prolonged incubation time on the results of the QuantiFERON TB Gold In-Tube assay for the diagnosis of latent tuberculosis infection
CVI Accepts, published online ahead of print on 3 July 2013 Clin. Vaccine Immunol. doi:10.1128/cvi.00290-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 Effect of prolonged
More informationInvestigation of false-positive results by the QuantiFERON-TB Gold In-Tube assay
JCM Accepts, published online ahead of print on 11 July 2012 J. Clin. Microbiol. doi:10.1128/jcm.00730-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Investigation of false-positive
More informationConflict of Interest Disclosures:
Mady Slater, M.D. Stanford University Medical Center Division of Infectious Diseases 04/23/14 WOEMA webinar Conflict of Interest Disclosures: I have no financial relationships with commercial entities
More informationTesting for TB. Bart Van Berckelaer Territory Manager Benelux. Subtitle
Testing for TB Bart Van Berckelaer Territory Manager Benelux Subtitle Agenda TB infection pathway TB immunisation Testing options Pre lab considerations of the whole blood ELISA test The T-SPOT.TB test
More informationDetecting latent tuberculosis using interferon gamma release assays (IGRA)
Detecting latent tuberculosis using interferon gamma release assays (IGRA) American Society for Microbiology June 2017 Edward Desmond, Ph.D., D (ABMM) San Lorenzo, CA Edward Desmond has no financial connections
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Interferon Gamma Release Assays Lisa Armitige, MD, PhD November 12, 2014 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of
More informationTB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 Interferon Gamma Release Assays (IGRA s) Lisa Armitige, MD, PhD October 16, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationMedicine, Stanford University School of Medicine, Stanford, CA, USA.
JCM Accepted Manuscript Posted Online 13 January 2016 J. Clin. Microbiol. doi:10.1128/jcm.02803-15 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 2 Interferon-γ release assays
More informationEvaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014
Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014 Interferon Gamma Release Assays: Understanding the Test David Griffith, BA, MD April 11, 2014 David Griffith, BA, MD has the following
More informationRichard N. van Zyl-Smit 1, Rannakoe J. Lehloenya 1,2, Richard Meldau 1, Keertan Dheda 1,3,4. Introduction
Original Article Impact of correcting the lymphocyte count to improve the sensitivity of TB antigen-specific peripheral blood-based quantitative T cell assays (T-SPOT. TB and QFT-GIT) Richard N. van Zyl-Smit
More informationThe Direct Comparison of Two Interferon-gamma Release Assays in the Tuberculosis Screening of Japanese Healthcare Workers
ORIGINAL ARTICLE The Direct Comparison of Two Interferon-gamma Release Assays in the Tuberculosis Screening of Japanese Healthcare Workers Masaki Tanabe 1, Akiko Nakamura 1, Akie Arai 1, Daisuke Yamasaki
More informationTB Intensive Tyler, Texas December 2-4, 2008
TB Intensive Tyler, Texas December 2-4, 2008 Interferon Gamma Releasing Assays: Diagnosing TB in the 21 st Century Peter Barnes, MD December 2, 2008 TOPICS Use of interferon-gamma release assays (IGRAs)
More informationTB Nurse Case Management San Antonio, Texas July 18 20, 2012
TB Nurse Case Management San Antonio, Texas July 18 20, 2012 IGRA s and Their Use in TB Nurse NCM Lisa Armitige, MD, PhD July 18, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationJournal of Infectious Diseases Advance Access published August 2, 2013
Journal of Infectious Diseases Advance Access published August 2, 2013 1 Reversion and Conversion of Interferon-gamma Release Assay Results in HIV-1 Infected Individuals Maximilian C. Aichelburg 1,*, Thomas
More informationApproaches to LTBI Diagnosis
Approaches to LTBI Diagnosis Focus on LTBI October 8 th, 2018 Michelle Haas, M.D. Associate Director Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES I have no disclosures or conflicts
More informationPeggy Leslie-Smith, RN
Peggy Leslie-Smith, RN EMPLOYEE HEALTH DIRECTOR - AVERA TRAINING CONTENT 1. South Dakota Regulations 2. Iowa Regulations 3. Minnesota Regulations 4. Interferon Gamma Release Assay (IGRA)Testing 1 SOUTH
More informationTB Prevention Who and How to Screen
TB Prevention Who and How to Screen 4.8.07. IUATLD 1st Asia Pacific Region Conference 2007 Dr Cynthia Chee Dept of Respiratory Medicine / TB Control Unit Tan Tock Seng Hospital, Singapore Cycle of Infection
More informationRESEARCH NOTE QUANTIFERON -TB GOLD IN-TUBE TEST FOR DIAGNOSING LATENT TUBERCULOSIS INFECTION AMONG CLINICAL-YEAR THAI MEDICAL STUDENTS
Southeast Asian J Trop Med Public Health RESEARCH NOTE QUANTIFERON -TB GOLD IN-TUBE TEST FOR DIAGNOSING LATENT TUBERCULOSIS INFECTION AMONG CLINICAL-YEAR THAI MEDICAL STUDENTS Benjawan Phetsuksiri 1, Somchai
More informationWithin-Subject Variability of Mycobacterium tuberculosis-specific Gamma Interferon Responses in German Health Care Workers
CLINICAL AND VACCINE IMMUNOLOGY, July 2011, p. 1176 1182 Vol. 18, No. 7 1556-6811/11/$12.00 doi:10.1128/cvi.05058-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Within-Subject
More informationLiterature Overview. Health Economics. Experience with QuantiFERON -TB Gold. Cellestis Clinical Guide series
Literature Overview Experience with QuantiFERON -TB Gold Health Economics Cellestis Clinical Guide series 2008 www.cellestis.com This literature overview is intended to provide healthcare professionals
More informationUse of an Interferon- Release Assay To Diagnose Latent Tuberculosis Infection in Foreign-Born Patients*
Original Research MYCOBACTERIAL DISEASE Use of an Interferon- Release Assay To Diagnose Latent Tuberculosis Infection in Foreign-Born Patients* Daniel Brodie, MD; David J. Lederer, MD, MS; Jade S. Gallardo,
More informationTechnical Bulletin No. 172
CPAL Central Pennsylvania Alliance Laboratory QuantiFERON -TB Gold Plus Assay Contact: J Matthew Groeller, MPA(HCM), MT(ASCP), 717-851-4516 Operations Manager, Clinical Pathology, CPAL Jennifer Thebo,
More informationEvaluation of QuantiFERON -TB Gold-Plus in Healthcare Workers in a Low- Incidence Setting
JCM Accepted Manuscript Posted Online 15 March 2017 J. Clin. Microbiol. doi:10.1128/jcm.02498-16 Copyright 2017 American Society for Microbiology. All Rights Reserved. 1 2 Evaluation of QuantiFERON -TB
More informationUsing Interferon Gamma Release Assays for Diagnosis of TB Infection
Learning Objectives Using Interferon Gamma Release Assays for Diagnosis of TB Infection 1. Describe available Interferon Gamma Release Assay tests for TB infection and how they work. 2. Understand interpretation
More informationAlbert Nienhaus 1,2* and José Torres Costa 3
Nienhaus and Costa Journal of Occupational Medicine and Toxicology 2013, 8:1 RESEARCH Open Access Screening for tuberculosis and the use of a borderline zone for the interpretation of the interferon-γ
More informationVariation in T-SPOT.TB spot interpretation between independent observers of different laboratories
8 Variation in T-SPOT.TB spot interpretation between independent observers of different laboratories Willeke P.J. Franken 1, Steven Thijsen 2, Ron Wolterbeek 3, John J.M. Bouwman 2, Hanane el Bannoudi
More informationRichard O Brien, Consultant, FIND 3 rd Global Symposium on IGRAs Waikoloa, Hawaii, 13 January 2012
Global l Applications of IGRAs Richard O Brien, Consultant, FIND 3 rd Global Symposium on IGRAs Waikoloa, Hawaii, 13 January 2012 Disclosure I have no personal financial conflicts of I have no personal
More informationInterferon-gamma release assay for treatment monitoring of active tuberculosis
JCM Accepts, published online ahead of print on 21 November 2012 J. Clin. Microbiol. doi:10.1128/jcm.02278-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Interferon-gamma
More informationTesting & Treatment for TB Infection: Blood Tests, Skin Tests, Who to Screen & Who to Treat?
NECHA 11/4/2016 Testing & Treatment for TB Infection: Blood Tests, Skin Tests, Who to Screen & Who to Treat? E. Jane Carter, M.D. Immediate Past President International Union Against TB and Lung Disease
More informationThorax Online First, published on December 8, 2009 as /thx
Thorax Online First, published on December 8, 2009 as 10.1136/thx.2009.119677 Title Page Cost effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the Quantiferon-TB gold
More informationBarbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast
Practical Aspects for Using the Interferon Gamma Release Assay (IGRA) Test Live Webinar July 14, 2017 Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and
More informationJCM Version 3. Utilization of the QuantiFERON-TB Gold Test in a 2-Step Process with the
JCM Accepts, published online ahead of print on 23 June 2010 J. Clin. Microbiol. doi:10.1128/jcm.02253-09 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationMycobacterial Infections: What the Primary Provider Should Know about Tuberculosis
Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening
More informationUse of Interferon-γ Release Assays (IGRAs) in TB control in low and middle-income settings - EXPERT GROUP MEETING -
Use of Interferon-γ Release Assays (IGRAs) in TB control in low and middle-income settings - EXPERT GROUP MEETING - Date and time: 20-21 July 2010, 09:00 18:00 Venue: Salle B, WHO-HQ, Geneva, Switzerland
More informationThe Challenges and Pitfalls in Diagnosing or Misdiagnosing Tuberculosis: Are the Days of TB Skin Tests Over?
The Challenges and Pitfalls in Diagnosing or Misdiagnosing Tuberculosis: Are the Days of TB Skin Tests Over? ROY F. CHEMALY, MD, MPH, FIDSA, FACP PROFESSOR OF MEDICINE DIRECTOR, INFECTION CONTROL SECTION
More informationIGRA Test Reliability. How Test Design and Lab Control Impact Results
IGRA Test Reliability How Test Design and Lab Control Impact Results IGRA Test Reliability Background Why IGRAs are uniquely challenging to both test manufacturers and labs Why complexity exists with both
More informationQuantiFERON-TB Gold Plus
QuantiFERON-TB Gold Plus A New Interferon-γ Release Assay (IGRA) for the Indirect Detection of Mycobacterium tuberculosis HOT TOPIC / 2018 Presenter: Elitza S. Theel, PhD, D(ABMM) Director of Infectious
More informationLaboratory Updates on IGRA Testing
Laboratory Updates on IGRA Testing Edward A. Graviss, PhD, MPH, FIDSA August 18, 2017 EXCELLENCE EXPERTISE INNOVATION Edward A. Graviss, PhD, MPH, FIDSA, has the following disclosures to make: No conflict
More informationIs the QuantiFERON-TB Blood Assay a Good Replacement for the Tuberculin Skin Test in Tuberculosis Screening? A Pilot Study at Berkshire Medical Center
Microbiology and Infectious Disease / QuantiFERON-TB Assay for TB Screening Is the QuantiFERON-TB Blood Assay a Good Replacement for the Tuberculin Skin Test in Tuberculosis Screening? A Pilot Study at
More informationUpdate on IGRA Predictive Value
Update on IGRA Predictive Value Sandra Kik, PhD Molebogeng Rangaka, MD, PhD Madhukar Pai, MD, PhD McGill International TB Centre, McGill University University of Cape Town & London School of Hygiene and
More informationDidactic Series. Latent TB Infection in HIV Infection
Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director, SF and North Coast AETC March 13, 2014 ACCREDITATION STATEMENT:
More informationDiagnosis Latent Tuberculosis. Disclosures. Case
Diagnosis Latent Tuberculosis Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention September 2016 1 Disclosures
More informationDiagnosis and Medical Case Management of Latent TB. Bryan Rock, MD April 27, 2010
TB Nurse Case Management Lisle, Illinois April 27-28, 28 2010 Diagnosis and Medical Case Management of Latent TB Infection Bryan Rock, MD April 27, 2010 DIAGNOSIS AND MANAGEMENT OF LATENT TUBERCULOSIS
More informationInterferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines
Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines Historically, Latent Tuberculosis Infection (LTBI) diagnosis was based on risk assessment, chest x-ray (CXR)
More informationThese recommendations will remain in effect until the national shortage of PPD solution has abated.
Maryland Recommendations Regarding the National Shortage of Purified Protein Derivative (PPD) Solution; Attachment to Health Officer Memorandum National Shortages of Tubersol and Aplisol for TB Skin Testing;
More informationQFT-Plus: a plus in variability? Evaluation of new generation IGRA in serial testing of students with a migration background in Germany
Knierer et al. Journal of Occupational Medicine and Toxicology (2017) 12:1 DOI 10.1186/s12995-016-0148-z RESEARCH Open Access QFT-Plus: a plus in variability? Evaluation of new generation IGRA in serial
More informationborderline range for Quantiferon Gold In-Tube Tube results Abstract Objective Methods Results Conclusions
RESEARCH ARTICLE A borderline range for Quantiferon Gold In- Tube results Jerker Jonsson 1,2, Anna Westman 3,4, Judith Bruchfeld 2,5, Erik Sturegård 6, Hans Gaines 1,2,5, Thomas Schön 7,8 * a1111111111
More informationIdentifying TB co-infection : new approaches?
Identifying TB co-infection : new approaches? Charoen Chuchottaworn MD. Senior Medical Advisor, Central Chest Institute of Thailand, Department of Medical Services, MoPH Primary tuberculosis Natural history
More informationPerformance of QuantiFERON-TB Gold and Tuberculin Skin Test Relative to Subjects Risk of Exposure to Tuberculosis
MAJOR ARTICLE Performance of QuantiFERON-TB Gold and Tuberculin Skin Test Relative to Subjects Risk of Exposure to Tuberculosis Sharon E. McMullen, 1 David A. Pegues, 2 Frances S. Shofer, 3 Alexandra C.
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed
More informationQualitative and quantitative results of interferon-γ release assays for monitoring the response to anti-tuberculosis treatment
ORIGINAL ARTICLE Korean J Intern Med 217;32:32-38 https://doi.org/1.394/kjim.216.199 Qualitative and quantitative results of interferon-γ release assays for monitoring the response to anti-tuberculosis
More informationIndeterminate test results of T-SPOT TM.TB performed under routine field conditions
Eur Respir J 2008; 31: 842 846 DOI: 10.1183/09031936.00117207 CopyrightßERS Journals Ltd 2008 Indeterminate test results of T-SPOT TM.TB performed under routine field conditions P. Beffa*, A. Zellweger
More informationDimitrios Vassilopoulos,* Stamatoula Tsikrika, Chrisoula Hatzara, Varvara Podia, Anna Kandili, Nikolaos Stamoulis, and Emilia Hadziyannis
CLINICAL AND VACCINE IMMUNOLOGY, Dec. 2011, p. 2102 2108 Vol. 18, No. 12 1556-6811/11/$12.00 doi:10.1128/cvi.05299-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Comparison
More informationAdachi et al. SpringerPlus 2013, 2:440 a SpringerOpen Journal
Adachi et al. SpringerPlus 2013, 2:440 a SpringerOpen Journal RESEARCH Open Access Tuberculosis examination using whole blood interferon-gamma release assay among health care workers in a Japanese hospital
More informationT-Cell Assays for Tuberculosis Infection: Deriving Cut- Offs for Conversions Using Reproducibility Data
T-Cell Assays for Tuberculosis Infection: Deriving Cut- Offs for Conversions Using Reproducibility Data Anandharaman Veerapathran 1,2, Rajnish Joshi 1,2,3, Kalyan Goswami 1,2, Sandeep Dogra 4, Erica E.
More informationTime interval to conversion of interferon-c release assay after exposure to tuberculosis
Eur Respir J 2011; 37: 1447 1452 DOI: 10.1183/09031936.00089510 CopyrightßERS 2011 Time interval to conversion of interferon-c release assay after exposure to tuberculosis S.W. Lee*,#, D.K. Oh ", S.H.
More informationThe Role of the Interferon Gamma Release Assay in Assessing Recent Tuberculosis Transmission in a Hospital Incident
The Role of the Interferon Gamma Release Assay in Assessing Recent Tuberculosis Transmission in a Hospital Incident Louise Bradshaw 1 *, Elizabeth Davies 2, Michael Devine 2, Peter Flanagan 2, Paul Kelly
More informationComparison of Quantiferon-TB Gold With Tuberculin Skin Test for Detecting Latent Tuberculosis Infection Prior to Liver Transplantation
American Journal of Transplantation 2007; 7: 2797 2801 Blackwell Munksgaard C 2007 The Authors Journal compilation C 2007 The American Society of Transplantation and the American Society of Transplant
More informationTuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA)
Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA) April 2019 Bob Belknap M.D. Director, Denver Metro TB Program Disclosures No relevant financial relationships Objectives Be able to
More informationNo, not these...or these.
Interpretation of IGRA Results - Session Commentary - Matthew J. Binnicker, Ph.D., D(ABMM) The Big Three: No, not these...or these. The Big Three: Commonly asked questions when interpreting IGRA results:
More informationEvaluation of an In Vitro Assay for Gamma Interferon Production in Response to Mycobacterium tuberculosis Infections
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, Nov. 2004, p. 1089 1093 Vol. 11, No. 6 1071-412X/04/$08.00 0 DOI: 10.1128/CDLI.11.6.1089 1093.2004 Copyright 2004, American Society for Microbiology. All
More informationTuberculosis Update. Topics to be Addressed
Tuberculosis Update Robert M. Jasmer, M.D. University of California, San Francisco TB Control Section, San Francisco Department of Public Health Topics to be Addressed TB in the USA Screening recommendations
More informationAn evaluation of the QuantiFERONÂ Gold tuberculosis-screening test for employees at the Portland Veterans Affairs Medical Center
Oregon Health & Science University OHSU Digital Commons Scholar Archive June 2013 An evaluation of the QuantiFERONÂ Gold tuberculosis-screening test for employees at the Portland Veterans Affairs Medical
More informationORIGINAL ARTICLE. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients
ERJ Express. Published on July 25, 2007 as doi: 10.1183/09031936.00040007 ORIGINAL ARTICLE Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients Yoshihiro Kobashi, Keiji Mouri, Yasushi
More informationTargeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University Tuberculosis Estimates USA World Infection 15,000,000 2,000,000,000
More informationReport on WHO Policy Statements
Report on WHO Policy Statements Christopher Gilpin TB Diagnostics and Laboratory Strengthening Unit Secretariat, Global Laboratory Initiative Stop TB Department, WHO Geneva New Diagnostics Working Group
More informationInterpretation of TST & IGRA results. Objectives
Interpretation of TST & IGRA results Randall Reves, MD, MSc Volunteer Clinician Denver Metro TB Program and Division of Infectious Diseases, Department of Medicine University of Colorado Denver Objectives
More informationDiagnosis and treatment of latent tuberculosis infection: an update
Curr Respir Care Rep (2013) 2:199 207 DOI 10.1007/s13665-013-0064-y RESPIRATORY INFECTIONS (CL DALEY, SECTION EDITOR) Diagnosis and treatment of latent tuberculosis infection: an update Anna K. Person
More informationCategory Description / Key Findings Publication
PUBLICATIONS Selected T-SPOT.TB test publications, by area of interest, up to 31 th August 2016. Category Description / Key Findings Publication Background A useful primer on the evolution, administration
More informationA Clinician s Perspective: Improving Rheumatology Patient Care Using the T-SPOT.TB Test
A Clinician s Perspective: Improving Rheumatology Patient Care Using the T-SPOT.TB Test Solomon Forouzesh, MD, FACD, FACR Medical Director Arthritis Care & Treatment Center Clinical Associate Professor
More informationUtility of PPD or IGRA to answer the age old question of "TB or not TB
Utility of PPD or IGRA to answer the age old question of "TB or not TB Thomas S. Alexander, Ph.D., D(ABMLI) Immunologist Summa Health alexandt@summahealth.org Yes, The reservation is in the name of Dr.
More informationCritical Evaluation of Tuberculosis Diagnostic Tests in Low- and High- Burden Settings
Critical Evaluation of Tuberculosis Diagnostic Tests in Low- and High- Burden Settings by John Metcalfe Dissertation submitted in partial satisfaction of the requirements for the degree of Doctor of Philosophy
More information2016 OPAM Mid-Year Educational Conference, Sponsored by AOCOPM Sunday, March 13, 2016
Learning Objectives Tuberculosis Case Discussions: Evaluation for Tuberculosis Infection Melissa C. Overman, DO, MPH, CHES, FAOCOPM Describe appropriate technique for TST placement, reading and interpretation
More informationIncidence of occupational latent tuberculosis infection in South African healthcare workers
ORIGINAL ARTICLE TUBERCULOSIS Incidence of occupational latent tuberculosis infection in South African healthcare workers Shahieda Adams 1,2, Rodney Ehrlich 2, Roslynn Baatjies 3, Richard N. van Zyl-Smit
More informationTuberculosis (TB) remains a major global. Are interferon-c release assays useful for diagnosing active tuberculosis in a high-burden setting?
Eur Respir J 2011; 38: 649 656 DOI: 10.1183/09031936.00181610 CopyrightßERS 2011 Are interferon-c release assays useful for diagnosing active tuberculosis in a high-burden setting? D.I. Ling*, M. Pai*,
More informationMædica - a Journal of Clinical Medicine
Mædica - a Journal of Clinical Medicine ORIGINAL PAPERS Prospective Comparison of Two Brands of Tuberculin Skin Tests and Quantiferon-TB Gold in-tube Assay Performances for Tuberculosis Infection in Hospitalized
More informationTargeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease
Self-Study Study Modules on Tuberculosis Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease 1 Module 3: Objectives At completion of this module, learners will
More informationDiagnostic challenges of active childhood TB in Tanzania. Michala Vaaben Rose, MD, Ph.D Department of Infectious Diseases, Hvidovre
Diagnostic challenges of active childhood TB in Tanzania Michala Vaaben Rose, MD, Ph.D Department of Infectious Diseases, Hvidovre 1 Diagnosis of Childhood Tuberculosis Muheza hospital, TZ Hilleroedhospital.dk
More informationClinical Policy Title: Interferon-gamma release assays for tuberculosis screening
Clinical Policy Title: Interferon-gamma release assays for tuberculosis screening Clinical Policy Number: 07.01.06 Effective Date: March 1, 2014 Initial Review Date: November 20, 2013 Most Recent Review
More informationCHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT]
CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT] QUESTION: : Which children in the United States should get a tuberculin skin test? Do questionnaires really work? Jeffrey
More informationScreening for Tuberculosis Infection. Harlingen, TX. Linda Dooley, MD has the following disclosures to make:
TB Infection Diagnosis Recommendations Talk Developed by Lisa Y. Armitige, MD, PhD Medical Consultant, Heartland National TB Center Associate Professor Internal Medicine/Pediatrics/Infectious Disease UT
More informationDiagnosis of tuberculosis
Diagnosis of tuberculosis Madhukar Pai, MD, PhD Assistant Professor, Epidemiology McGill University, Montreal, Canada madhukar.pai@mcgill.ca Global TB Case Detection A major concern 2.6 million new smear
More informationClinical evaluation of QuantiFERON TB-2G test for immunocompromised patients
Eur Respir J 2007; 30: 945 950 DOI: 10.1183/09031936.00040007 CopyrightßERS Journals Ltd 2007 Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients Y. Kobashi, K. Mouri, Y. Obase,
More informationPrevalence and risk factors of latent tuberculosis infection among health care workers in Malaysia
RESEARCH ARTICLE Open Access Prevalence and risk factors of latent tuberculosis infection among health care workers in Malaysia Shaharudin Rafiza 1*, Krishna Gopal Rampal 2, Aris Tahir 3 Abstract Background:
More informationShort-Term Reproducibility of a Commercial Interferon Gamma Release Assay
CLINICAL AND VACCINE IMMUNOLOGY, Aug. 2009, p. 1170 1175 Vol. 16, No. 8 1556-6811/09/$08.00 0 doi:10.1128/cvi.00168-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Short-Term
More informationLTBI-Tuberculin skin test. T-Spot.TB Technology. QuantiFERON -TB Gold In Tube T-SPOT.TB ELISA ELISA
LTBI-Tuberculin skin test QuantiFERON -TB Gold In Tube ELISA PPD ~200 antigens 3 ml blood ESAT-6 TB 7.7 16-24 hour incubation Nil Negative control PHA Positive control Andersen et al Lancet 2000;356:1099-1104
More informationT-CELL RESPONSES ASSESSED USING IGRA AND TST ARE NOT CORRELATED WITH AFB GRADE AND CHEST RADIOGRAPH IN PULMONARY TUBERCULOSIS PATIENTS
T-CELL RESPONSES ASSESSED USING IGRA AND TST ARE NOT CORRELATED WITH AFB GRADE AND CHEST RADIOGRAPH IN PULMONARY TUBERCULOSIS PATIENTS Kiatichai Faksri 1, 4, Wipa Reechaipichitkul 2, 4, Wilailuk Pimrin
More informationReceived 8 February 2007/Returned for modification 20 March 2007/Accepted 10 April 2007
CLINICAL AND VACCINE IMMUNOLOGY, June 2007, p. 714 719 Vol. 14, No. 6 1556-6811/07/$08.00 0 doi:10.1128/cvi.00073-07 Copyright 2007, American Society for Microbiology. All Rights Reserved. Comparison of
More informationClinical Policy Title: Interferon-gamma release assays for tuberculosis screening
Clinical Policy Title: Interferon-gamma release assays for tuberculosis screening Clinical Policy Number: 07.01.06 Effective Date: March 1, 2014 Initial Review Date: November 20, 2013 Most Recent Review
More informationCOMPARISON OF TWO INTERFERON-G ASSAYS AND
3 COMPARISON OF TWO INTERFERON-G ASSAYS AND CONTACTS Sandra M. Arend 1, Steven F.T. Thijsen 2, Eliane M.S. Leyten 1, John J.M. Bouwman 2, Willeke P.J. Franken 1 3, Frank G.J. Cobelens 4,5, Arend-Jan van
More informationNew Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents
New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [With great thanks to Andrea
More informationKeywords: tuberculosis; IFN-g release assays; diagnostics; reproducibility
Reproducibility of Interferon Gamma (IFN-g) Release Assays A Systematic Review Saloua Tagmouti 1, Madeline Slater 2, Andrea Benedetti 3,4, Sandra V. Kik 3,4, Niaz Banaei 5, Adithya Cattamanchi 6, John
More informationThe tuberculin skin test (TST) was until recently the
Rapid diagnosis of Mycobacterium tuberculosis infection in children using interferon-gamma release assays (IGRAs) Shahla Riazi, M.D., 1,2 Barbara Zeligs, 1,2 Henry Yeager, M.D., 3 Stephen M. Peters, Ph.D.,
More informationQuantiFERON-TB Gold In-Tube Test for Tuberculosis Prevention in HIV-Infected Patients
Jpn. J. Infect. Dis., 70, 502 506, 2017 Original Article QuantiFERON-TB Gold In-Tube Test for Tuberculosis Prevention in HIV-Infected Patients Thana Khawcharoenporn 1 *, Benjawan Phetsuksiri 2, Janisara
More informationInterferon-gamma release assays for the tuberculosis serial testing of health care workers: a systematic review
Ringshausen et al. Journal of Occupational Medicine and Toxicology 2012, 7:6 RESEARCH Open Access Interferon-gamma release assays for the tuberculosis serial testing of health care workers: a systematic
More informationTuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA)
Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA) April 2018 Bob Belknap M.D. Director, Denver Metro TB Program No Disclosures Objectives be able to describe: 1. Who should get tested
More informationWhat the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Microbiology Epidemiology Common disease presentations Diagnosis of active
More informationJeffrey R. Starke, M.D. has the following disclosures to make:
AAP 2018 Red Book Tuberculosis: IGRAs and Treatment of TB Infection Jeffrey R. Starke, M.D. May 31, 2018 AAP 2018 Red Book Childhood Tuberculosis: IGRAs and Treatment of TB Infection May 31, 2018 WEBINAR
More information